Teleflex Incorporated (NYSE: TFX) has completed patient enrollment in the BIOMAG™-LL Clinical Study, which is evaluating 35 mm and 40 mm lengths of the Freesolve™ Resorbable Magnesium Scaffold (RMS) for treating coronary lesions up to 38 mm in length.

A total of 102 patients were enrolled across 14 European centers. The study is a premarket, prospective, international, multi-center, single-arm trial. Its primary endpoint is the Target Lesion Failure rate at 12 months, with clinical follow-up scheduled at 1, 6, 12, 36, and 60 months post-procedure.

The 35 mm and 40 mm scaffold lengths are also included in the ongoing BIOMAG™-III Pivotal Clinical Trial, which is currently enrolling patients in the United States and other international markets.

The current Freesolve™ RMS size matrix offers diameters of 2.5 mm, 3.0 mm, 3.5 mm, and 4.0 mm, and lengths of 13 mm, 18 mm, 22 mm, 26 mm, and 30 mm. The Freesolve™ RMS is commercially available in CE-mark accepting countries only and is not approved for sale in the United States.

Prof. Dr. Georg Nollert, Vice President Medical Affairs at Teleflex, said the study "represents an important step in expanding the Freesolve™ RMS portfolio to address longer coronary lesions." Prof. Flavio Ribichini, a paid consultant of Teleflex, noted that data from the study "will help determine whether longer Freesolve™ Scaffolds can expand treatment options for patients with longer lesions."

Information in this article is based on a press release issued by Teleflex.